Bladder Cancer

P=N/A, N=40, Recruiting, Icahn School of Medicine at Mount Sinai

P=N/A, N=400, Recruiting, Ferring Pharmaceuticals | N=800 --> 400

NGS, with its capacity for comprehensive genomic analysis, excels in detecting diverse genetic alterations, offering superior resolution compared to CMA. This study supports the use of the PGDx elio tissue complete panel as a compelling alternative to CMA, showcasing its accuracy in assessing the HRD phenotype. The observed high concordance rate further enhances its value in the clinical diagnostic setting.

P2, N=17, Active, not recruiting, National Cancer Institute (NCI) | N=209 --> 17 | Trial completion date: Jun 2024 --> Nov 2025

P2, N=80, Not yet recruiting, American University of Beirut Medical Center

P2, N=34, Recruiting, University of Florida | Not yet recruiting --> Recruiting

P1/2, N=250, Recruiting, Daiichi Sankyo | Trial primary completion date: Dec 2024 --> Dec 2025

P1, N=169, Completed, Astellas Pharma Global Development, Inc. | Phase classification: P1b --> P1

P2, N=40, Not yet recruiting, Case Comprehensive Cancer Center | Initiation date: Aug 2024 --> Mar 2025

P2, N=23, Not yet recruiting, University of California, Irvine

P=N/A, N=200, Not yet recruiting, Istituto Oncologico Veneto IRCCS | Trial completion date: Jun 2026 --> Jun 2027 | Initiation date: Mar 2024 --> Dec 2024

P1/2, N=19, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=12 --> 19

P=N/A, N=132, Not yet recruiting, The First Affiliated Hospital, Zhejiang University School of Medicine; The First Affiliated Hospital, Zhejiang University School of Medicine

P=N/A, N=80, Recruiting, Shanghai General Hospital, Shangahi Jiao Tong University School of Medicine; Shanghai General Hospital, Shangahi Jiao Tong University School of Medici

P=N/A, N=60, Not yet recruiting, The Affiliated Hospital of Qingdao University; The Affiliated Hospital of Qingdao University

P2, N=61, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center

P1, N=120, Not yet recruiting, Department of Anesthesiology and Perioperative Medicine, the First Affiliated Hospital of Nanjing Medical University; the First Affiliated Hospital of

Conclusions BE could allow a reduction in the number of cystoscopies in the follow-up of HR-NMIBC, with a potential improvement in the quality of life of patients, given its high NPV. Management of a positive BE must be individualized for each patient, with a high Se for non-LG recurrence in HR-NMIBC patient.

P1, N=9, Completed, Mayo Clinic | Active, not recruiting --> Completed

P=N/A, N=15, Not yet recruiting, Amsterdam UMC

RNF19A suppressed the proliferation, migration, and invasion abilities of BCa cells by regulating ILK ubiquitination and inactivating the AKT/mTOR signalling pathway. RNF19A might be a potential prognostic biomarker and promising therapeutic target for BCa.

In the RC group, tumor multiplicity, age ≥75 years, and lack of postoperative adjuvant therapy are independent risk factors for overall survival. Female sex is an independent risk factor affecting prognosis in the BPS group.

The identification of distinct molecular clusters with varying prognoses and immune cell infiltrations highlights the heterogeneity of BLCA and underscores the potential of CPRGs as biomarkers for prognosis and therapeutic targets. These findings offer new perspectives for the development of immunotherapeutic strategies in the treatment of BLCA patients, potentially leading to more personalized and effective cancer therapies.

No abstract available

These results confirmed that dasatinib is a potent chemotherapeutic drug which induces apoptosis and autophagy by suppressing the PI3K/Akt/mTOR pathway in bladder cancer cells.

These findings underscore the pivotal role of CAF-related genes in prognostic prediction for BUC patients. Clinical decision-making and tailored therapeutics stand to benefit from these results, providing a valuable reference for future research endeavors.

P1, N=272, Active, not recruiting, Genentech, Inc. | Trial completion date: Nov 2024 --> Mar 2025 | Trial primary completion date: Nov 2024 --> Mar 2025

Lastly, the drug sensitivity analysis revealed that the BLCA cells in the high-risk group showed an increased sensitivity to cisplatin, sunitinib, cetuximab, axitinib, docetaxel, saracatinib, vinblastine and pazopanib compared with those in the low-risk group. According to the Quantitative real time PCR results, we found that five lncRNAs of the risk model were more highly expressed in BCa cell lines than human immortalized uroepithelial cell line. The disulfidptosis-related lncRNA risk model has a valuable effect in assessing the prognosis of BLCA patients.

Deleterious DDR alterations were associated with pathologic response following NAC in S1314. Functional validation of ERCC2 and other DDR alterations is underway to help refine such alterations as biomarkers of NAC in patients with bladder cancer.

P3, N=186, Completed, Sun Yat-sen University | Unknown status --> Completed

P3, N=520, Active, not recruiting, Merck Sharp & Dohme LLC | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2029 --> Jan 2027

P=N/A, N=420, Not yet recruiting, IRCCS San Raffaele

P1, N=190, Recruiting, Pfizer | Not yet recruiting --> Recruiting

P1, N=10, Completed, Protara Therapeutics | Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Sep 2024

This study identified significant biomarkers associated with urological cancers in blood and urine. These include GGT, IGF 1, and Lp(a), which are strong biomarkers for PCa. In addition, the findings of this study provide evidence for a handful of risk and protective factors for the development of urologic cancers.

Our findings suggest that TGF-β expression can remarkably predict a worse prognosis in patients with bladder cancer. The results of the present meta-analysis may be validated through further updated reviews and additional relevant investigations in future studies.

This study validates the performance of a previously developed urine assay in an unselected cohort of HR-NMIBC patients under surveillance. With a robust sensitivity/specificity and a strong anticipatory effect, this assay proves a useful adjunct ready for evaluation in a future randomized controlled trial.

P2, N=96, Completed, Queen Mary University of London | Unknown status --> Completed

Additionally, 2,6-DBBQ and 2,6-DCBQ may have produced excessive reactive oxygen species, damaging DNA and chromosomes. These results not only first confirm the potential carcinogenicity of 2,6-DBBQ and 2,6-DCBQ but also provide an important reference for exploring the cytotoxicity and genotoxicity mechanisms of these HBQs.

In conclusion, our results demonstrate that by activating c-Myc/miR-613/NCL axis, ISO treatment results in BECN1 posttranscriptional upregulation, which specifically initiates LC3B-dependent autophagy and anti-cancer activity. Our findings further strengths our application of ISO for therapy of high-grade invasive BC (HGIBC) patients.

No significant correlation was found between protein profiles in malignant tissue. All in all, BCL-2 and γ-H2AX did not prove to be candidate markers for UBC clinical management in the present sample, despite their expression in malignant bladder tissue.

We also identified several samples with high mutation burden between ADAR1 and other genes regulated primarily in endometrial cancers. Finally, we show that the deaminase domain is highly conserved in metazoans and mutations within conserved residues do occur in human cancers suggesting that destabilization of the enzyme function is contributing to cancer development.